Back to all studies
RecruitingNCT06506019

Neurobiological Effects of Psilocybin in Treatment Resistant Depression in bipolarity

This study is recruiting. It focuses on bipolarity and currently lists participation information in Canada.

BipolarityOtherFrom 18 Years to 65 Years
Need help deciding?

Ask HopeStage to review this study with me

Leave your email and HopeStage can help you better understand this study.

Loading the security check...
Study reference: NCT06506019. HopeStage can help you review the study, but cannot decide medical eligibility.
In plain English

Key information made simple

This study is looking at whether a digital support tool can help people with Depression in bipolarity. Participants receive a study treatment and complete follow-up visits and assessments. Taking part may give some people access to a digital support tool, but direct benefit is not guaranteed.

What to expect

Your next step

The official record suggests in-person participation through a hospital, with sites including Toronto Western Hospital - University Health Network. Participation appears to involve assessments along with scans or samples to help researchers understand patterns more clearly. The main fit is usually being able to understand the study and consent, while common reasons not to take part include pregnancy or breastfeeding and active substance or alcohol problems that could affect the results. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Sponsor
University Health Network, Toronto
Sponsor type
University
Main activity
digital app or tool
Intervention
Not available
Time commitment
long follow-up or multiple visits
Study phase
Not available
Enrollment
Not available
Recruitment status
Recruiting
Source
Official registry link
Public study data

Key study information

Official title
Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression
Condition
Bipolar Depression
Study status
Recruiting
Sponsor / lead affiliation
University Health Network, Toronto
Location / country
Canada
Registry
ClinicalTrials.gov
External trial ID
NCT06506019
Why this study may matter

Why this study may matter

This study may matter because it adds public evidence around bipolarity. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.

In practice

For you

Taking part may help clarify how this condition is measured or understood.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in Canada.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Official title
Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression
Source
ClinicalTrials.gov
Official registry link
Open official registry
External trial ID
NCT06506019
Open source record
Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is Neurobiological Effects of Psilocybin in Treatment Resistant Depression in bipolarity?

This study is exploring digital app or tool for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.

Who is behind this study, and what type of sponsor is it?

This study is sponsored by University Health Network, Toronto. Based on the sponsor name or official registry information, it appears to be a university. You should verify the details in the official registry record.

What does participation involve, what phase is it, and what should I ask about safety?

This study may involve digital app or tool, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.

Where can I verify the study details?

Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Neurobiological Effects of Psilocybin in Treatment Resistant. — Bipolarity Clinical Trial | HopeStage